Carolyne K Smith1, Nickie L Seto1, Anuradha Vivekanandan-Giri2, Wenmin Yuan3, Martin P Playford4, Zerai Manna5, Sarfaraz A Hasni5, Rui Kuai3, Nehal N Mehta4, Anna Schwendeman3, Subramaniam Pennathur2, Mariana J Kaplan1. 1. Systemic Autoimmunity Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, Maryland, USA. 2. Division of Nephrology, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA. 3. Department of Medicinal Chemistry, The Biointerfaces Institute, University of Michigan, Ann Arbor, Michigan, USA. 4. Section of Inflammation and Cardiometabolic Diseases, National Heart, Lung and Blood Institute, NIH, Bethesda, Maryland, USA. 5. Lupus Clinical Research Program, Office of the Clinical Director, NIAMS/NIH, Bethesda, Maryland, USA.
Abstract
OBJECTIVES: Recent evidence indicates that high-density lipoprotein (HDL) exerts vasculoprotective activities by promoting activating transcription factor 3 (ATF3), leading to downregulation of toll-like receptor (TLR)-induced inflammatory responses. Systemic lupus erythematosus (SLE) is associated with increased cardiovascular disease risk not explained by the Framingham risk score. Recent studies have indicated oxidised HDL as a possible contributor. We investigated the potential mechanisms by which lupus HDL may lose its anti-inflammatory effects and promote immune dysregulation. METHODS: Control macrophages were challenged with control and SLE HDL in vitro and examined for inflammatory markers by real-time qRT-PCR, confocal microscopy, ELISA and flow cytometry. Lupus-prone mice were treated with an HDL mimetic (ETC-642) in vivo and inflammatory cytokine levels measured by real-time qRT-PCR and ELISA. RESULTS: Compared with control HDL, SLE HDL activates NFκB, promotes inflammatory cytokine production and fails to block TLR-induced inflammation in control macrophages. This failure of lupus HDL to block inflammatory responses is due to an impaired ability to promote ATF3 synthesis and nuclear translocation. This inflammation is dependent on lectin-like oxidised low-density lipoprotein receptor 1 (LOX1R) binding and rho-associated, coiled-coil containing protein kinase 1 and 2 (ROCK1/2) kinase activity. HDL mimetic-treated lupus mice showed significant ATF3 induction and proinflammatory cytokine abrogation. CONCLUSIONS: Lupus HDL promotes proinflammatory responses through NFκB activation and decreased ATF3 synthesis and activity in an LOX1R-dependent and ROCK1/2-dependent manner. HDL mimetics should be explored as potential therapies for inflammation and SLE cardiovascular risk. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/.
OBJECTIVES: Recent evidence indicates that high-density lipoprotein (HDL) exerts vasculoprotective activities by promoting activating transcription factor 3 (ATF3), leading to downregulation of toll-like receptor (TLR)-induced inflammatory responses. Systemic lupus erythematosus (SLE) is associated with increased cardiovascular disease risk not explained by the Framingham risk score. Recent studies have indicated oxidised HDL as a possible contributor. We investigated the potential mechanisms by which lupus HDL may lose its anti-inflammatory effects and promote immune dysregulation. METHODS: Control macrophages were challenged with control and SLE HDL in vitro and examined for inflammatory markers by real-time qRT-PCR, confocal microscopy, ELISA and flow cytometry. Lupus-prone mice were treated with an HDL mimetic (ETC-642) in vivo and inflammatory cytokine levels measured by real-time qRT-PCR and ELISA. RESULTS: Compared with control HDL, SLE HDL activates NFκB, promotes inflammatory cytokine production and fails to block TLR-induced inflammation in control macrophages. This failure of lupus HDL to block inflammatory responses is due to an impaired ability to promote ATF3 synthesis and nuclear translocation. This inflammation is dependent on lectin-like oxidised low-density lipoprotein receptor 1 (LOX1R) binding and rho-associated, coiled-coil containing protein kinase 1 and 2 (ROCK1/2) kinase activity. HDL mimetic-treated lupus mice showed significant ATF3 induction and proinflammatory cytokine abrogation. CONCLUSIONS: Lupus HDL promotes proinflammatory responses through NFκB activation and decreased ATF3 synthesis and activity in an LOX1R-dependent and ROCK1/2-dependent manner. HDL mimetics should be explored as potential therapies for inflammation and SLE cardiovascular risk. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/.
Authors: H M Berman; J Westbrook; Z Feng; G Gilliland; T N Bhat; H Weissig; I N Shindyalov; P E Bourne Journal: Nucleic Acids Res Date: 2000-01-01 Impact factor: 16.971
Authors: Masashi Suzuki; David K Pritchard; Lev Becker; Andrew N Hoofnagle; Natsuko Tanimura; Theo K Bammler; Richard P Beyer; Roger Bumgarner; Tomas Vaisar; Maria C de Beer; Frederick C de Beer; Kensuke Miyake; John F Oram; Jay W Heinecke Journal: Circulation Date: 2010-10-25 Impact factor: 29.690
Authors: Eneida Villanueva; Srilakshmi Yalavarthi; Celine C Berthier; Jeffrey B Hodgin; Ritika Khandpur; Andrew M Lin; Cory J Rubin; Wenpu Zhao; Stephen H Olsen; Matthew Klinker; David Shealy; Michael F Denny; Joel Plumas; Laurence Chaperot; Matthias Kretzler; Allen T Bruce; Mariana J Kaplan Journal: J Immunol Date: 2011-05-25 Impact factor: 5.422
Authors: Maureen McMahon; Jennifer Grossman; Brian Skaggs; John Fitzgerald; Lori Sahakian; Nagesh Ragavendra; Christina Charles-Schoeman; Karol Watson; Weng Kee Wong; Elizabeth Volkmann; Weiling Chen; Alan Gorn; George Karpouzas; Michael Weisman; Daniel J Wallace; Bevra H Hahn Journal: Arthritis Rheum Date: 2009-08
Authors: Dominic De Nardo; Larisa I Labzin; Hajime Kono; Reiko Seki; Susanne V Schmidt; Marc Beyer; Dakang Xu; Sebastian Zimmer; Catharina Lahrmann; Frank A Schildberg; Johanna Vogelhuber; Michael Kraut; Thomas Ulas; Anja Kerksiek; Wolfgang Krebs; Niklas Bode; Alena Grebe; Michael L Fitzgerald; Nicholas J Hernandez; Bryan R G Williams; Percy Knolle; Manfred Kneilling; Martin Röcken; Dieter Lütjohann; Samuel D Wright; Joachim L Schultze; Eicke Latz Journal: Nat Immunol Date: 2013-12-08 Impact factor: 25.606
Authors: Philip M Carlucci; Monica M Purmalek; Amit K Dey; Yenealem Temesgen-Oyelakin; Simantini Sakhardande; Aditya A Joshi; Joseph B Lerman; Alice Fike; Michael Davis; Jonathan H Chung; Martin P Playford; Mohammad Naqi; Pragnesh Mistry; Gustavo Gutierrez-Cruz; Stefania Dell'Orso; Faiza Naz; Taufiq Salahuddin; Balaji Natarajan; Zerai Manna; Wanxia L Tsai; Sarthak Gupta; Peter Grayson; Heather Teague; Marcus Y Chen; Hong-Wei Sun; Sarfaraz Hasni; Nehal N Mehta; Mariana J Kaplan Journal: JCI Insight Date: 2018-04-19
Authors: Sarfaraz A Hasni; Sarthak Gupta; Michael Davis; Elaine Poncio; Yenealem Temesgen-Oyelakin; Philip M Carlucci; Xinghao Wang; Mohammad Naqi; Martin P Playford; Rishi R Goel; Xiaobai Li; Ann J Biehl; Isabel Ochoa-Navas; Zerai Manna; Yinghui Shi; Donald Thomas; Jinguo Chen; Angélique Biancotto; Richard Apps; Foo Cheung; Yuri Kotliarov; Ashley L Babyak; Huizhi Zhou; Rongye Shi; Katie Stagliano; Wanxia Li Tsai; Laura Vian; Nathalia Gazaniga; Valentina Giudice; Shajia Lu; Stephen R Brooks; Meggan MacKay; Peter Gregersen; Nehal N Mehta; Alan T Remaley; Betty Diamond; John J O'Shea; Massimo Gadina; Mariana J Kaplan Journal: Nat Commun Date: 2021-06-07 Impact factor: 14.919
Authors: Rebecca L Schill; Darcy A Knaack; Hayley R Powers; Yiliang Chen; Moua Yang; Daniel J Schill; Roy L Silverstein; Daisy Sahoo Journal: FEBS J Date: 2019-08-14 Impact factor: 5.622